PBMD Prima BioMed Ltd

2.47
+0  (1%)
Previous Close 2.44
Open 2.43
Price To book 2.22
Market Cap 51.20M
Shares 20,730,000
Volume 5,499
Short Ratio 1.48
Av. Daily Volume 48,719

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b interim data released December 22, 2016.
IMP321
Breast cancer

Latest News

  1. Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial
  2. Prima BioMed Receives A$492,144 Tax Refund From Australian Government
  3. Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
  4. First Half 2017 Operational Update
  5. Prima BioMed Bets Big on Cancer Drug IMP321
  6. Prima BioMed Receives ~A$860,000 Tax Credit Payment From French Government
  7. ($$) Temasek, Others Plan to Sell Stake in Indonesian Retailer
  8. Prima Biomed Initiates Randomized Study for Breast Cancer
  9. Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference
  10. Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer
  11. Prima BioMed to Maintain NASDAQ Listing
  12. Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
  13. Prima BioMed Enters New Material Transfer Agreement With CYTLIMIC
  14. Prima Announces New Product Candidate IMP761 -- A LAG-3 Agonist Antibody
  15. Prima (PBMD) Reports Favorable Initial Melanoma Study Data
  16. Prima BioMed Announces First Clinical Data From Combination of IMP321 With Anti-PD1
  17. Prima BioMed Announces Data From IMP321 AIPAC Clinical Trial in Breast Cancer
  18. Prima BioMed Receives UK Approval for AIPAC Study
  19. Prima BioMed Announces ADR Ratio Change from 30 Ordinary Share to 100